overal believ thermo fisher stori remain strong come
earn despit move part usual print specif
thermo fisher post organ growth comp expect
previous disclos data center outag repres headwind underli
growth remain top amongst life scienc tool peer importantli thermo
fisher key growth driver remain intact compani post dd growth
biopharma mid-teen growth china compani ad bioproduct
busi post fastest growth compani report earn far
would impli given strong result peer thermo fisher deliv
top line beat versu forecast appl appl time dynam
margin came modestli forecast op margin vs forecast
adj ep beat expect includ
core ebit beat well benefit below-the-lin item
look believ thermo fisher forecast appear conserv given
compani strategi uniqu growth driver aforement time
dynam compani forecast revenu billion
midpoint billion previous increas
upper end lower end midpoint
encourag better oper trend drove rais guidanc
impli rais organ growth expect ep project rang
y/i midpoint similarli major
rais came stronger oper expect account
guidanc rais overal view underli trend quarter consist
believ thesi around thermo fisher industry-lead strategi
return equiti ttm
link barclay live interact chart
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight thermo fisher market leader
across divers portfolio life scienc tool
diagnost impress global reach across
custom class end market compani
consist track record organ growth capit
deploy manag execut
recommend share core hold exposur
innov healthcar
see upsid thermo fisher target driven
continu biopharma strength well futur
capit deploy upsid case reflect
upsid ep
thermo fisher exposur econom activ
end market could impact growth
specif industri end market repres
around revenu downsid case
reflect downsid ep
overal believ thermo fisher stori remain strong come
earn despit move part usual print specif thermo
fisher post organ growth comp expect previous
disclos data center outag repres headwind underli growth
driver remain intact compani post dd growth biopharma mid-teen
growth china compani ad bioproduct busi post fastest
growth compani report earn far would impli given
strong result peer thermo fisher deliv top line beat versu
forecast appl appl time dynam margin came modestli
forecast op margin vs forecast adj ep beat
expect includ core ebit beat well
benefit below-the-lin item
look believ thermo fisher forecast appear conserv given
compani strategi uniqu growth driver aforement time dynam
compani forecast revenu billion midpoint
billion previous increas upper end
lower end midpoint encourag better
oper trend drove rais guidanc impli rais organ growth
expect ep project rang y/i
midpoint similarli major rais came stronger
oper expect account guidanc rais overal view
underli trend quarter consist believ thesi around thermo
fisher industry-lead strategi differenti busi mix remain intact
maintain overweight rate price target note pull gatan part
roper cover julian mitchel acquisit forecast given
announc acquisit longer move forward due uk
review deal price target repres adj ep forecast
previous repres prior adj ep forecast
thermo fisher updat guidanc reflect stronger oper less advers
fx ep line later expect close anatom patholog sale
revenu expect rang midpoint
reflect report revenu growth organ growth still expect
rang rais rel previou guidanc
addit revenu guidanc emb fx headwind net
tailwind advanc bioprocess asset bd expect contribut
anatom patholog sale base close expect
headwind due time deal close brammer
base acquisit expect tailwind manag
commentari suggest biopharma growth year expect rang
hsd-low dd industri growth forecast modest assum lsd
ep project rang repres growth
repres rais midpoint previou guidanc stronger
oper less advers fx due time anatom
patholog sale guidanc emb dilut ap sale headwind
tariff embed guidanc also share repurchas complet
januari debt repay oper margin forecast
modestli previou guidanc believ due
increment fx headwind remind tariff ap sale expect repres
headwind though compani pars impact brammer
margin absolut basi ap sale expect ebit headwind
guidanc assum tax rate y/i net interest expens
line prior guidanc share count line prior guidanc
revenu billion came better estim billion
grew y/i driven mostli better organ growth higher
vs model fx roughli line vs model organ
growth y/i better forecast thermo fisher origin
messag growth would level lower forecast
preview account compani datacent outag quarter end
consist compani impact view perform solid
context comp biopharma dd organ growth china mid-teen
continu repres notabl growth driver thermo fisher addit believ
impli analyt instrument organ growth headlin adjust
segment impact data center highlight compani like continu
perform well cryo-em chromatographi mass spectrometri
quarterli revenu mm total organ growth
store revenu growth segment
revenu contribut segment
industri end market commentari solid importantli compani saw
continu strength biopharma end market double-digit growth y/i
confer call manag elabor trend experienc
market academ govern end market rel flat on-going strength
china mute condit north america europ healthcar diagnost
grew low-singl digit strong contribut immunodiagnost
clinic diagnost healthcar market channel thermo fisher achiev double-
digit growth biopharma repres continu recent trend strength
broad-bas compani highlight bioproduct pharma servic notabl
industri appli experienc low singl digit growth driven strong demand
chemic analysi chromatography/mass spectrometri
manag commentari quarter
geograph commentari strong highlight mid-teen growth china
despit difficult comparison demand asia-pacif continu strong hsd growth
highlight strength china thermo fisher remain encourag china
market custom behavior region remain encourag thermo fisher
expect neg chang go forward littl exposur gener food
continu fine compani deliv mid-singl digit growth north america
europ point mute condit academ govern end market
compani elabor condit europ continu stabl consist
macroeconom condit rest world region declin lsd
scienc growthmor mutedmodest growthstrong growthstrong growthveri growthgrowth leadergrowth leaderveri growthexcel growthbiosciencesstrong demandparticularli strong growthstrong growthstrong growthstrong growthveri growthgrowth leadergrowth leaderveri growthl growthnext sequencingstrong demandstrong growthveri growthgrowth leadergrowth leaderveri growthet analysisstrong demandveri growthanalyt appliedgrew compani averag appli safeti channel industrialgrew compani averag appli return growth chemicalmsd growth good china growthmsd growthhsd growthmsd growthhsd growth strong across aihsd strong across ailsdmass specstrong growthstrong growthstrong growthstrong growthstrong growthveri growthveri growthveri growthveri growthl growthchromatographystrong growthstrong growthstrong growthstrong growthstrong growthveri growthveri growthveri growthveri growthl growthelectron microscopi fei compani strong oper executionexcel oper performancedouble-digit growthstrong growthstrong growthveri growthveri growthveri growthveri growthlsd growthspecialti dx clinic dxsimilar trend lsd strength clinic ngstransplant particularli stronglsd growth transplant immunodiagnosticslsd strong season busi clinic transplant dxlsd particularli strong healthcar channelmsd transplant clinic diagnost channelmsd channel transplant clinic diagnosticsmsd channel transplant immunodx clinic diagnosticsmsd immunodx clinic diagnosticsmsd clinic diagnost immunodx channellab product govtlsd growthlsd growthmsd growth europ chinahsd growthmsd growthhsd growthmsd growthmsd growthlsd growthflatpharma biotechhsd growthmsd growthmsd growthmid-teen growthhigh-teen growthlow-teen growthdouble-digitdouble-digitbiopharma servicesunfavor mix biopharma servicesunfavor mix biopharma servicesunfavor mix biopharma servicesgrow wellstrong growthstrong growthstrong growthstrong growthstrong growthexcel growth barclay thermo fisher scientif inc
detail thermo
driver pleas see report
detail thermo
offer see
biopharma biz make
higher growth
thought
landscap viral
vector pleas see
thought viral vector
expect focu confer call relat thermo fisher
bioproduct busi appear post healthi growth
quarter manag optimist long-term driver bioproduct
market believ
custom valu proposit posit compani well
manag commentari suggest thermo fisher bioproduct busi continu
outgrow market compani see strong demand industry-lead
single-us cell cultur media product line furthermor compani believ
recent announc acquisit brammer bring import capabl
specif confer call ceo marc casper note start pharma
end market strong deliv anoth quarter double-digit
growth continu see strength across busi serv custom
excel momentum bioproduct pharma servic busi uniqu valu
proposit reson extrem well biopharma custom see us
strateg partner help acceler innov pipelin enhanc
product across busi also comment recent capit
deploy target area given leadership serv pharma
biotech end market focus enhanc valu bring
custom expand exist capabl
complement strateg acquisit give coupl exampl
expans project continu increas bioproduct capabl meet
robust custom demand recent commit million expand manufactur
network lead singl use technolog also announc plan establish
new bioprocess collabor center pharma servic site st loui missouri
terrif exampl combin bioproduct technolog pharma
servic capabl benefit custom drive growth term acquisit
pleas continu acquisit brammer leader viral vector
manufactur gene cell therapi discuss detail analyst
meet may brammer significantli expand offer fast-grow market
give us opportun leverag capabl gene therapi across
bioscienc bioproduct pharma servic busi set new standard
among life scienc tool peer believ thermo fisher uniqu capabl serv
biopharma end market under-appreci long-term differenti
growth driver compani altogeth biopharma end market repres around
thermo fisher revenu grown least m-hsd compani
foundat start research capabl channel busi consolid
histor driven growth thermo fisher aggreg client wallet thermo
fisher capabl product qa/qc continu perform well global access
therapeut drive demand liquid chromatographi beyond thermo fisher
uniqu capabl repres around revenu includ bioproduct
growthhsd growthldd growthjust americalsd growthhsd growthlsd growthmsd growthhsd growthhsd growthmsd growthmsd growtheuropemsd growthlsd growthmsd growthmsd growthmsd growthhsd growthhsd growthhsd growthmsd growthmsd growthrowflatflatmsd growthlow-teensmsd growthlow-teenshsd growthmsd growthdouble-digitsdown lsd barclay thermo fisher scientif inc
contract drug manufactur patheon clinic trial logist see sustain
long-term growth driver hsd-low-teen segment believ
long-term structur tailwind support visibl import growth driver
thermo fisher uniqu biopharma exposur repres revenu mm
life scienc solut total organ
growth estim life scienc solut revenu came expect
billion increas y/i stronger organ growth drove revenu beat thermo
fisher bioproduct busi continu notabl growth driver within
compani lss segment quarter currenc roughli headwind growth
line estim headwind acquisit bd advanc
bioprocess asset ad growth quarter close segment
oper incom million quarter increas y/i adjust
oper margin y/i
thru total trial total total biopharma total fisher biopharma contribut organ growthrevscdmo patheonorgan growthrevsclin trial logisticsorgan growthrevsbioproductionorgan growth barclay thermo fisher scientif inc
analyt instrument total organ
growth estim analyt instrument revenu increas y/i organ
currenc headwind quarter line estim headwind
describ due data center outag one thermo fisher facil
compani experienc overal headwind organ growth delay order
process shipment headwind roughli concentr
analyt instrument segment impli could headwind
segment organ growth context despit difficult comp organ
growth view underli trend healthi chemic analysi
chromatographi mass spec continu perform well expect thermo fisher
materi structur analysi segment slow quarter acquisit net
divestur contribut growth quarter segment oper incom
decreas y/i million oper margin
y/i given lost sale increment margin surpris see
specialti diagnost total organ
growth estim specialti diagnost result solid though organ revenu came
modestli expect organ growth vs forecast currenc
headwind quarter line estim headwind report
revenu improv rel model thermo fisher benefit later
expect sale anatom patholog busi model
headwind growth sale complet quarter adjust
oper incom decreas y/i million oper margin
y/i
laboratori product servic total
organ growth estim laboratori product servic segment revenu came
expect quarter total revenu increas y/i organ
revenu increas commentari thermo fisher biopharma servic busi
strong quarter keep mind patheon transact annual end
august busi contribut fulli organ growth quarter
acquisit brammer ad growth quarter close currenc
headwind line model adjust ebit increas y/i
million oper margin y/i
non-gaap ep increas y/i came better
estim adjust data center outag
better street unclear mani analyst proactiv updat
model compani tax rate expect
share count roughli line share line item ad
quarterli earn
non-gaap ep growth
adjust oper incom billion came forecast
grew y/i oper margin improv y/i came
expect gross margin lower
expect wherea sg revenu came better
expect expens revenu line expect
adj oper incom mm growth
oper margin improv y/i
flow oper billion adjust net incom
work capit strong quarter million gain cash cffo
came million expect capital-expenditure million came
forecast repres revenu y/i thermo fisher deploy
million dividend sharehold manag repurchas share
quarter come addit activ recent histori recent close
acquisit brammer april sale anatom patholog busi june
estim thermo fisher end quarter net debt ttm ebitda
flexibl pursu acquisit modest repurchas
opportun present
cffo compon trend cffo free capital-expenditure mm
thermo fisher continu activ capit deploy believ
compani continu flexibl pursu larg model assum
compani exit net debt ebitda target level
histor period compani lever start
thermo fisher acquir integenx march tuck-in deal area rapid forens
thermo fisher complet acquisit cover
return million sharehold dividend million share
repurchas recent compani announc acquisit brammer
march addit juli thermo fisher complet
sale anatom patholog busi billion cash phc hold
corpor also thermo fisher repurchas million share januari
call ceo casper note thermo fisher activ pipelin given
substanti flexibl addit attract opportun present
term free cash flow project thermo fisher gener billion
estim thermo fisher end quarter net debt ttm ebitda
net debt ttm ftm ebitda
flowcffo net debt ttm ebitdanet debt ntm ebitda barclay thermo fisher scientif inc
march thermo fisher announc acquisit brammer
view acquisit natur strateg fit thermo fisher augment
compani biopharma servic capabl one leader
manufactur viral vector gene cell therapi background viral vector
critic build block gene therapi manufactur brammer
posit one go-to outsourc manufactur viral vector
project across clinic develop commerci manufactur brammer
one larger manufactur market compet stand-alone
cdmo transact close may pleas see observ two
thermo fisher commentari regard deal
januari thermo fisher announc sale anatom patholog
busi billion cash phc hold corpor ap busi
one area thermo fisher portfolio compani lack scale
compet market roch cover emmanuel papadaki agil
dako among other anatom patholog gener revenu
channel busi addit busi rel
laggard specialti diagnost segment histor thermo fisher
divestitur improv underli segment growth deal close juli
octob thermo fisher complet million acquisit
bioprocess asset busi provid technic servic
pepton enhanc cell cultur media natur fit thermo fisher upstream
bioproduct offer cell cultur media single-us technolog asset
gener around million revenu estim around million
ebitda assum asset gener similar margin thermo fisher
bioproduct busi today modestli lss averag
acquisit expect add ep
patheon clearli excit around acquisit believ
signific opportun take share win busi improv
profit asset remind billion acquisit patheon close
end august part lab product servic divis
acquisit make thermo fisher one market leader
contract drug
manufactur own patheon thermo fisher believ remov element
complex suppli chain biopharma custom mani biopharma
sponsor thermo fisher largest supplier spend weve seen
cro industri industri pressur sponsor led consolid number
trust supplier choos work similarli small mid-siz biotech
compani dont capabl manufactur api drug
thermo fisher see natur cross-sel opportun compani clinic
trial logist busi given thermo fisher scale biopharma servic like
biopharma sponsor alreadi work compani clinic
trial logist patheon provid logic hand-ov clinic trial logist busi
drug manufactur thermo fisher provid pack ship servic
trial lot risk handoff clinic trial work
thermo fisher believ
industri consolid around time
addit custom also need cold chain servic thermo fisher provid
charg real value-ad servic custom thermo fisher
intend keep ad capit select franchis time continu
strategi patheon pursu stand-alon entiti
thermo fisher note patheon track ahead deal model term
integr deal accret remind thermo fisher guid investor
year accret million ebit cost revenu synergi
year term revenu synergi million year million
ebit thermo fisher note alreadi receiv inbound request cross-
sell clinic trial logist addit thermo fisher brand credibl
custom make natur partner outsourc work aggreg
share compani see pipelin small molecul biotech
choic outsourc thermo fisher count
signific amount chang outsourc penetr could repres
upsid term cost synergi million year beyond natur area
opportun public compani cost duplic administr area procur
better util manufactur footprint would provid lot earn
leverag thermo fisher see lot under-capac site own patheon
combin factor expect push margin mid-teen
compani averag time ceo marc casper note expans
st loui facil expect complet late
fei co believ thermo fisher acquisit fei co fit well compani
 strategi re-emphas call fei co bring market lead
platform electron microscopi microscop compani believ em
platform complement portfolio mass spectrometri certain applic
specif highlight protein identif character thermo
fisher also highlight intend drive adopt fei technolog
biopharma market compani differenti product portfolio c-level
relationship help extend fei co reach thermo fisher impress fei
manufactur facil brno czech republ plan leverag site notabl
first month ownership thermo fisher note accret
compani forecast remind fei annual
count toward organ growth base result recent cryo-em survey
higher level convict sustain demand fei full
detail survey see page report outlook tool
thermo fisher mm except ep reportedincom growth profit ebitda ebit pre-tax pre-tax tax net net researchprior yearprior quarter barclay thermo fisher scientif inc
estestestestestestincom statement growth growth growth organ adj product product product revenu inc servic servic gross margin inc sg stock comp total sg product margin oper incom margin improv w/ improv annual bs annual bs debt item expens pre-tax tax benefit net averag sharesbas ep continu opsbas adj adj full-year barclay thermo fisher scientif inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
